Wall Street brokerages expect that Becton Dickinson and Co (NYSE:BDX) will report earnings per share of $2.61 for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Becton Dickinson and’s earnings. The highest EPS estimate is $2.66 and the lowest is $2.54. Becton Dickinson and posted earnings per share of $2.30 in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.5%. The company is scheduled to report its next earnings report before the market opens on Thursday, May 3rd.
On average, analysts expect that Becton Dickinson and will report full year earnings of $10.95 per share for the current year, with EPS estimates ranging from $10.89 to $11.00. For the next financial year, analysts anticipate that the business will report earnings of $12.62 per share, with EPS estimates ranging from $12.44 to $12.86. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business earned $2.33 EPS.
Several equities analysts recently commented on BDX shares. Zacks Investment Research lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Citigroup raised shares of Becton Dickinson and from a “neutral” rating to a “buy” rating and increased their price objective for the company from $237.00 to $251.00 in a research report on Tuesday. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. KeyCorp started coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They issued an “overweight” rating and a $260.00 price objective for the company. Finally, Bank of America reaffirmed a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research report on Friday, January 19th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $241.19.
Shares of Becton Dickinson and stock traded up $1.92 during midday trading on Monday, hitting $225.37. The company had a trading volume of 962,077 shares, compared to its average volume of 1,168,332. The firm has a market capitalization of $59,491.88, a P/E ratio of 23.77, a PEG ratio of 1.62 and a beta of 1.15. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and has a 12-month low of $175.66 and a 12-month high of $248.39.
The firm also recently declared a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 31.65%.
In other news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total transaction of $426,079.00. Following the sale, the executive vice president now owns 15,387 shares of the company’s stock, valued at approximately $3,492,849. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John E. Gallagher sold 5,346 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the sale, the vice president now directly owns 9,391 shares in the company, valued at approximately $2,123,117.28. The disclosure for this sale can be found here. Insiders have sold a total of 281,108 shares of company stock valued at $61,321,396 over the last three months. 1.00% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Zions Bancorporation grew its stake in shares of Becton Dickinson and by 23.7% during the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock worth $2,100,000 after purchasing an additional 2,050 shares during the period. BlackRock Inc. grew its stake in shares of Becton Dickinson and by 6.0% during the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after purchasing an additional 1,071,288 shares during the period. Cigna Investments Inc. New grew its stake in shares of Becton Dickinson and by 11.8% during the 4th quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock worth $2,085,000 after purchasing an additional 1,025 shares during the period. Wagner Wealth Management LLC acquired a new stake in shares of Becton Dickinson and during the 4th quarter worth approximately $154,000. Finally, Westpac Banking Corp grew its stake in shares of Becton Dickinson and by 23.9% during the 4th quarter. Westpac Banking Corp now owns 110,619 shares of the medical instruments supplier’s stock worth $23,679,000 after purchasing an additional 21,369 shares during the period. 83.41% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “$2.61 Earnings Per Share Expected for Becton Dickinson and Co (BDX) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/14/2-61-earnings-per-share-expected-for-becton-dickinson-and-co-bdx-this-quarter.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Get a free copy of the Zacks research report on Becton Dickinson and (BDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.